SECsense Logo

Alnylam Pharmaceuticals 8-K Report: Key Updates on January 12, 2025

$ALNY
Form 8-K
Filed on: 2025-01-13
Source
Alnylam Pharmaceuticals 8-K Report: Key Updates on January 12, 2025

Based on the provided XBRL section of the financial report, here are the key pieces of information extracted:

  1. Company Information:
  • Company Name: Alnylam Pharmaceuticals, Inc.
  • CIK Number: 0001178670
  • State of Incorporation: Delaware (DE)
  • Business Address: 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142
  • Contact Number: 617-551-8200
  1. Filing Details:
  • Filing Form: 8-K (which is used to report unscheduled material events or corporate changes)
  • Filing Date: January 12, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.01 per share
  • Ticker Symbol: ALNY
  • Exchange: NASDAQ
  1. Reporting Period:
  • Start Date: January 12, 2025
  • End Date: January 12, 2025
  1. Contextual Information:
  • The document is filed using XBRL format, which is a standard for digital financial reporting.
  • The schema reference for the filing is linked to "alny-20250112.xsd".

Insights:

  • The filing is a current report (8-K), indicating that Alnylam Pharmaceuticals has reported a significant event or information that shareholders and the SEC need to be informed about immediately.
  • The report is dated the same day it was filed, suggesting it pertains to an event or announcement that occurred on the same date.
  • Given that the report is associated with a biotechnology company (Alnylam Pharmaceuticals), stakeholders would likely be interested in the nature of the event reported, which could impact stock performance or strategic direction. Further details would be needed to assess the implications of the information disclosed in the 8-K filing.